BioVie Inc. Finite-Lived Intangible Asset, Expected Amortization, Year One
BioVie Inc. (BIVI) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $57.34 thousand as of 2025-03-31, per its 10-Q filed 2025-05-12.
Financial Statements › Notes › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2025-05-12
- 2025-03-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $57.34K.
- 2024-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $114.69K.
- 2024-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $172.03K.
- 2024-03-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $57.34K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2025-03-31 | $57.34K 10-Q · filed 2025-05-12 |
| 2024-12-31 | $114.69K 10-Q · filed 2025-02-11 |
| 2024-09-30 | $172.03K 10-Q · filed 2024-11-13 |
| 2024-03-31 | $57.34K 10-Q · filed 2024-05-14 |
| 2023-12-31 | $114.69K 10-Q · filed 2024-02-13 |
| 2023-09-30 | $172.03K 10-Q · filed 2023-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |